Business Wire

Oral-B’s Virtual Experience at 2021 Consumer Electronics Show Puts the Power to Control Health in Consumers’ Hands with the Oral-B iO™

11.1.2021 18:00:00 EET | Business Wire | Press release

Share

During a time when many things feel out of our control, people have taken stock of their health and are seeking ways to make a meaningful, positive impact – all from the comfort of home.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210111005188/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The Oral-B iO Experience at the P&G LifeLab Everyday virtual platform at the 2021 Consumer Electronics Show (CES). (Photo: Business Wire)

This year, at the 2021 Consumer Electronics Show (CES), Oral-B will highlight its commitment to powering the smallest daily habits, such as using an electric toothbrush, to create the biggest positive impact on the health of your whole body, whole family and the whole planet, through its first ever virtual experience.

Located within P&G’s LifeLab Everyday virtual platform, the virtual experience will highlight Oral-B iO, the brand’s most innovative toothbrush, reimagined and redesigned from the inside out to remove 100% more plaque than a manual toothbrush.

  • The unique dentist-inspired round brush head is designed to surround each tooth with its micro-vibrating bristles to reach below the gumline for a deep, professional clean feeling every day.
  • The bimodal smart pressure sensor is the first of its kind to provide positive brushing feedback, identifying and guiding users to brush in the optimal pressure range to protect gums and enamel.
  • The Linear Magnetic Drive System delivers controlled, consistent movements from the handle to brush tips, producing gentle micro-vibrations for a more enjoyable experience and efficiently transferring more energy directly to the bristle tips.
  • The Smart Display with Personalized Brushing Modes offers an intuitive interface that provides coaching and motivation throughout the cleaning process and features up to seven brush modes for a highly personalized experience.

And this all comes together with Artificial Intelligence Tracking via the Oral-B iO App. It provides real-time individual tracking and coaching, thanks to artificial intelligence informed by thousands of recorded brushing sessions. Oral-B iO has a simple and intuitive user interface that guides consumers through a two-minute brushing session with 3D teeth tracking to ensure a professional clean feeling every time.

Recently, Oral-B partnered with Scientific American to further explore and understand the new research and innovations transforming our understanding of the connection between oral health and overall health.

“Over 700 studies substantiate the notion that great oral health habits can be a simple step in improving one’s overall health,” explains Jeremy A. Abbate, VP & Publisher at Scientific American, “Gum disease is the mouth’s way of warning us of potentially more serious issues to come, so it’s important to heed those early warnings.”

Those warning signs can be as small as bleeding gums or tooth loss but can lead to more severe conditions such as heightened pregnancy complications, cognitive loss and more than double the risk of cardiovascular disease and diabetes.

In clinical tests, Oral-B iO provided a deeper cleaning of teeth and gums, allowing users to easily and effectively maintain oral health. Oral-B iO users experienced:

  • 100 percent healthier gums in just one week, when compared to manual toothbrushes
  • 6 times more plaque removal along the gumline, when compared to manual toothbrushes
  • 83 percent of gingivitis patients moved from unhealthy to healthy gums in eight weeks

Lisa Ernst, Senior Vice President, Research & Development, Oral Care stated, “An Oral-B electric toothbrush is a powerful first step in being proactive against the risks associated with gum disease. We give consumers the power to take control of their families’ health at home with Oral-B iO, which helps prevent and reduce gingivitis for the best gum health.”

In addition, P&G’s LifeLab Everyday will feature P&G Oral Care’s newest sustainability commitments to advance healthy oral care habits to transform the health of people while reducing our impact on our planet. Healthy habits for the environment mean a world where everyone respects our planet and its natural resources by:

  • Turning off the tap when brushing your teeth
  • Recycling packaging and products
  • Unplugging the toothbrush charger when not in use.

For more information on Oral-B iO, please visit oralb.com.

About Oral-B

Oral-B® is the worldwide leader in the over $5 billion brushing market. Part of the Procter & Gamble Company, the brand includes manual and electric toothbrushes for children and adults, oral irrigators and interdental products, such as dental floss.

About Procter & Gamble

P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always®, Ambi Pur®, Ariel®, Bounty®, Charmin®, Crest®, Dawn®, Downy®, Fairy®, Febreze®, Gain®, Gillette®, Head & Shoulders®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, SK-II®, Tide®, Vicks®, and Whisper®. The P&G community includes operations in approximately 70 countries worldwide. Please visit http://www.pg.com for the latest news and information about P&G and its brands. For other P&G news, visit us at www.pg.com/news.

About Procter & Gamble’s LifeLab Everyday:

At P&G’s LifeLab Everyday is a new virtual platform that reveals how innovation at Procter & Gamble is reinventing consumer experiences and making progress toward a better future for our society and our planet. The exhibit combines robust, consumer-based insights with breakthrough science inspired by how people live, work, play.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

P&G Oral Care Communications
Velvet Gogol Bennett
gogolbennett.vc@pg.com
or
MSLGROUP
Meredith Lowe, 860-305-6975
meredith.lowe@mslgroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 14:30:00 EEST | Press release

Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye